Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6533
    +0.0010 (+0.15%)
     

  • OIL

    83.85
    +0.28 (+0.34%)
     

  • GOLD

    2,349.40
    +6.90 (+0.29%)
     

  • Bitcoin AUD

    97,582.18
    -1,057.42 (-1.07%)
     

  • CMC Crypto 200

    1,323.84
    -72.70 (-4.99%)
     

  • AUD/EUR

    0.6106
    +0.0033 (+0.54%)
     

  • AUD/NZD

    1.0992
    +0.0034 (+0.31%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,768.05
    +337.55 (+1.94%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • Dow Jones

    38,309.20
    +223.40 (+0.59%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Chimerix to Present at Wedbush PacGrow Healthcare Conference

Chimerix, Inc.
·1-min read
Chimerix, Inc.
Chimerix, Inc.

DURHAM, N.C., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend lives of patients facing deadly diseases, today announced that Chimerix management will participate in the Targeted Oncology panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 10:20 a.m.

A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACTS:
        
Michelle LaSpaluto
919 972-7115
ir@chimerix.com 

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com